AnaptysBio (AN6) AI Stock Analysis

0 Followers

AnaptysBio

(Frankfurt:AN6)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Current profitabilityThe latest results show a substantial profitability inflection, with strong net income and operating margins. If this earnings improvement is supported by collaboration economics and licensing activity, it can provide meaningful internal funding capacity and improve strategic flexibility over the next several quarters.

Negative Factors

Revenue contractionRevenue contraction weakens confidence that the latest profit level represents a steadily expanding operating base. For a company relying on collaboration and licensing economics, lower revenue can signal uneven deal timing or reduced commercial contribution, making future earnings and cash generation less predictable.

AnaptysBio (AN6) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.38B
Dividend Yield: ―
Average Volume (3M): 154
Price to Earnings (P/E): 7.3
Beta (1Y): 0.43
Revenue Growth: 8.60%
EPS Growth: ―
Country: Germany
Employees: 104
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete wh...

AnaptysBio Risk Analysis

AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Risks Related to Ownership of Our Common StockQ1, 2026

2.Risks Related to Our Recent SeparationQ1, 2026

3.Risks Related to Intellectual PropertyQ1, 2026

AnaptysBio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:AN6 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZYME	62Neutral	$1.83B	39.16	22.48%	―	97.78%	―
XNCR	61Neutral	$2.78B	-23.62	-21.29%	―	33.55%	11.51%
CGEM	59Neutral	$667.39M	-3.14	-59.06%	―	―	10.29%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRVS	51Neutral	$897.52M	-14.38	-34.98%	―	―	-272.40%
CTMX	47Neutral	$444.73M	-4.52	-33.97%	―	-87.66%	-210.45%

* Healthcare Sector Average

Performance Comparison

DE:AN6 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AN6	AnaptysBio	42.91	23.47	120.74%
XNCR	Xencor Inc.	37.09	21.47	137.45%
CTMX	CytomX Therapeutics Inc.	2.04	-1.51	-42.54%
CRVS	Corvus Pharmaceuticals Inc.	10.64	1.73	19.42%
ZYME	Zymeworks	26.24	2.34	9.79%
CGEM	Cullinan Therapeutics Inc	10.28	1.51	17.22%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AnaptysBio AI Stock Analysis